Clinical and outcome data of the patients analyzed for MRD
UPN . | DG . | Age (y) . | BCR-ABL1 variant . | Initial treatment protocol . | Initial WBC . | Initial CNS involvement . | TKI . | SCT . | Relapse (mo) . | Death (mo) . | Status . | Follow-up (mo) . | BCR-ABL1 vs Ig/TCR MRD . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A0752 | ALL | 5 | Major | ALL BFM 95 | 360 000 | No | Frontline | CR2 | 5 | — | CR2 | 177 | Discordant |
A1071 | ALL | 11 | Minor | ANZCCSG Study 7 | 530 000 | No | Frontline | CR1 | 16 | 30 | Exitus | — | Concordant |
A1861 | ALL | 5 | Minor | ANZCHOG Study 8 | 1400 | No | Frontline | CR1 | — | — | CR1 | 144 | Concordant |
A1862 | ALL | 4 | Minor | ANZCHOG Study 8 | 19 700 | No | Frontline | CR1 | — | — | CR2 | 128 | Concordant |
A2184 | ALL | 13 | Minor | ANZCHOG Study 8 | 28 100 | No | Frontline | CR1 | 22 | — | CR2 | 104 | Concordant |
A2504 | ALL | 10 | Minor | ANZCHOG Study 8 | 8500 | No | Frontline | CR1 | 55 | — | CR2 | 126 | Concordant |
A4643 | ALL | 14 | Minor | ANZCHOG Study 8 | 6000 | No | Frontline | CR1 | — | — | CR1 | 93 | Concordant |
A5017 | ALL | 4 | Major | ANZCHOG Study 8 | 917 000 | Yes | Frontline | CR1 | — | — | CR1 | 88 | Concordant |
A5020 | ALL | 7 | Minor | ANZCHOG Study 8 | 148 000 | No | Frontline | No | 40 | 41 | Exitus | — | Concordant |
A5219 | ALL | 5 | Minor | COG AALL0031 | 17 100 | No | Frontline | CR1 | — | — | CR1 | 70 | Discordant |
A5295 | ALL | 14 | Major | Individualized therapy | 321 500 | No | Frontline | CR1 | 33 | 55 | Exitus | — | Concordant |
A5444 | ALL | 8 | Minor | ANZCHOG Study 8 | 59 400 | No | Frontline | No | — | — | CR1 | 63 | Concordant |
A5659 | ALL | 11 | Minor | COG AALL0232 | 14 800 | No | Frontline | No | — | — | CR1 | 51 | Concordant |
A5751 | ALL | 11 | Minor | AIEOP-BFM ALL 2009 | 4200 | No | Frontline | No | 46 | — | CR2 | 46 | Concordant |
A5925 | ALL | 10 | Major | COG AALL1131 | 267 800 | No | Frontline | CR1 | — | 8 | Exitus | — | Concordant |
A6002 | ALL | 15 | Minor | Individualized therapy | 337 400 | No | Frontline | CR1 | — | — | CR1 | 36 | Concordant |
A6036 | ALL | 4 | Minor | COG AALL1112/CA180372 | 9500 | No | Frontline | No | — | — | CR1 | 33 | NA |
C3 | ALL | 10 | Minor | ALL BFM 90 | 114 600 | No | No | CR1 | 58 | — | CR4 | 145 | Concordant |
C4 | ALL | 15 | Minor | ALL BFM 90 | 8200 | No | After relapse | CR2 | 116 | — | CR2 | 204 | Discordant |
C198 | ALL | 10 | Minor | ALL BFM 95 | 23 600 | No | No | No | 10 | 15 | Exitus | — | Discordant |
C212 | ALL | 4 | Minor | ALL BFM 95 | 125 000 | No | After relapse | CR2 | 112 | — | CR2 | 214 | Concordant |
C375 | ALL | 6 | Minor | ALL BFM 95 | 6800 | No | Frontline | CR2 | 33 | — | CR2 | 198 | Concordant |
C429 | ALL | 4 | Minor | ALL BFM 95 | 100 900 | No | After relapse | CR2 | 33 | — | CR2 | 194 | Discordant |
C438 | ALL | 10 | Minor | ALL BFM 95 | 32 000 | No | Frontline | CR2 | 15 | 46 | Exitus | — | Concordant |
C533 | ALL | 9 | Minor | ALL BFM 95 | 41 600 | No | Frontline | CR1 | 27 | 28 | Exitus | — | Concordant |
C658 | ALL | 11 | Minor | ALL IC-BFM 2002 | 40 000 | No | After relapse | CR2 | 26 | — | CR2 | 160 | Discordant |
C710 | ALL | 12 | Major | EsPhALL | 139 000 | No | Frontline | CR1 | — | — | CR1 | 153 | Concordant |
C718 | ALL | 4 | Minor | EsPhALL | 24 900 | No | Frontline | CR1 | — | — | CR1 | 152 | Concordant |
C769 | ALL | 14 | Minor | EsPhALL | 45 000 | Yes | Frontline | CR1 | 17 | 19 | Exitus | — | Concordant |
C825 | ALL | 5 | Minor | EsPhALL | 145 000 | No | Frontline | CR1 | 18 | 19 | Exitus | — | Concordant |
C861 | ALL | 17 | Major | ALL IC-BFM 2002 | 190 800 | Yes | Frontline | CR1 | — | — | CR1 | 137 | Concordant |
C1029 | ALL | 13 | Major | EsPhALL | 135 000 | No | Frontline | CR1 | — | 18 | Exitus | — | Concordant |
C1092 | ALL | 4 | Minor | EsPhALL | 184 700 | No | Frontline | CR1 | 10 | 10 | Exitus | — | Discordant |
C1277 | ALL | 3 | Minor | EsPhALL | 154 000 | No | Frontline | CR1 | — | 12 | Exitus | — | Concordant |
C1304 | ALL | 2 | Minor | COG AALL0622 | 133 630 | Yes | Frontline | CR1 | 31 | — | CR3 | 87 | Concordant |
C1382 | ALL | 5 | Minor | EsPhALL | 9500 | Yes | Frontline | No | — | 3 | Exitus | — | Discordant |
C1519 | ALL | 4 | Minor | EsPhALL | 344 000 | No | Frontline | CR2 | 34 | 42 | Exitus | — | Concordant |
C1822 | ALL | 11 | Minor | EsPhALL | 411 500 | Yes | Frontline | CR2 | 28 | — | CR2 | 45 | Concordant |
C1893 | ALL | 17 | Minor | EsPhALL | 6670 | No | Frontline | No | — | — | CR1 | 40 | Discordant |
C1964 | ALL | 14 | Minor | EsPhALL | 5900 | No | Frontline | CR1 | — | — | CR1 | 36 | NA* |
C2248 | ALL | 10 | Minor | EsPhALL | 155 200 | No | Frontline | No | — | — | CR1 | 20 | Concordant |
C2294 | ALL | 14 | Major | EsPhALL | 65 600 | Yes | Frontline | No | — | — | CR1 | 20 | Concordant |
G001 | ALL | 7 | Major | ALL BFM 2000 | 46 000 | No | No | CR1 | — | — | CR1 | 145 | Discordant |
G002 | ALL | 16 | Major | ALL BFM 2000 | 135 000 | Yes | Frontline | CR1 | 14 | 46 | Exitus | — | Discordant |
G003 | ALL | 3 | Minor | ALL BFM 2000 | 1950 | No | Frontline | CR2 | 33 | — | CR2 | 140 | Discordant |
G004 | ALL | 14 | Major | EsPhALL | 49 600 | No | Frontline | CR1 | — | — | CR1 | 98 | Discordant |
G005 | ALL | 14 | Major | EsPhALL | 167 900 | No | Frontline | CR1 | — | — | CR1 | 67 | Discordant |
G006 | ALL | 18 | Minor | EsPhALL | 760 | No | Frontline | CR2 | 84 | — | CR2 | 92 | Discordant |
C543 | CML | 12 | Major | ALL BFM 95 | 194 200 | No | Frontline | CR1 | 9 | 12 | Exitus | — | Discordant |
C1123 | CML | 6 | Major | CML PaedII-06 | 575 000 | No | Frontline | CR2 | 2 | — | CR2 | 108 | Discordant |
C1437 | CML | 14 | Major | EsPhALL | 477 000 | No | Frontline | CR1 | 11 | 13 | Exitus | — | Discordant |
UPN . | DG . | Age (y) . | BCR-ABL1 variant . | Initial treatment protocol . | Initial WBC . | Initial CNS involvement . | TKI . | SCT . | Relapse (mo) . | Death (mo) . | Status . | Follow-up (mo) . | BCR-ABL1 vs Ig/TCR MRD . |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A0752 | ALL | 5 | Major | ALL BFM 95 | 360 000 | No | Frontline | CR2 | 5 | — | CR2 | 177 | Discordant |
A1071 | ALL | 11 | Minor | ANZCCSG Study 7 | 530 000 | No | Frontline | CR1 | 16 | 30 | Exitus | — | Concordant |
A1861 | ALL | 5 | Minor | ANZCHOG Study 8 | 1400 | No | Frontline | CR1 | — | — | CR1 | 144 | Concordant |
A1862 | ALL | 4 | Minor | ANZCHOG Study 8 | 19 700 | No | Frontline | CR1 | — | — | CR2 | 128 | Concordant |
A2184 | ALL | 13 | Minor | ANZCHOG Study 8 | 28 100 | No | Frontline | CR1 | 22 | — | CR2 | 104 | Concordant |
A2504 | ALL | 10 | Minor | ANZCHOG Study 8 | 8500 | No | Frontline | CR1 | 55 | — | CR2 | 126 | Concordant |
A4643 | ALL | 14 | Minor | ANZCHOG Study 8 | 6000 | No | Frontline | CR1 | — | — | CR1 | 93 | Concordant |
A5017 | ALL | 4 | Major | ANZCHOG Study 8 | 917 000 | Yes | Frontline | CR1 | — | — | CR1 | 88 | Concordant |
A5020 | ALL | 7 | Minor | ANZCHOG Study 8 | 148 000 | No | Frontline | No | 40 | 41 | Exitus | — | Concordant |
A5219 | ALL | 5 | Minor | COG AALL0031 | 17 100 | No | Frontline | CR1 | — | — | CR1 | 70 | Discordant |
A5295 | ALL | 14 | Major | Individualized therapy | 321 500 | No | Frontline | CR1 | 33 | 55 | Exitus | — | Concordant |
A5444 | ALL | 8 | Minor | ANZCHOG Study 8 | 59 400 | No | Frontline | No | — | — | CR1 | 63 | Concordant |
A5659 | ALL | 11 | Minor | COG AALL0232 | 14 800 | No | Frontline | No | — | — | CR1 | 51 | Concordant |
A5751 | ALL | 11 | Minor | AIEOP-BFM ALL 2009 | 4200 | No | Frontline | No | 46 | — | CR2 | 46 | Concordant |
A5925 | ALL | 10 | Major | COG AALL1131 | 267 800 | No | Frontline | CR1 | — | 8 | Exitus | — | Concordant |
A6002 | ALL | 15 | Minor | Individualized therapy | 337 400 | No | Frontline | CR1 | — | — | CR1 | 36 | Concordant |
A6036 | ALL | 4 | Minor | COG AALL1112/CA180372 | 9500 | No | Frontline | No | — | — | CR1 | 33 | NA |
C3 | ALL | 10 | Minor | ALL BFM 90 | 114 600 | No | No | CR1 | 58 | — | CR4 | 145 | Concordant |
C4 | ALL | 15 | Minor | ALL BFM 90 | 8200 | No | After relapse | CR2 | 116 | — | CR2 | 204 | Discordant |
C198 | ALL | 10 | Minor | ALL BFM 95 | 23 600 | No | No | No | 10 | 15 | Exitus | — | Discordant |
C212 | ALL | 4 | Minor | ALL BFM 95 | 125 000 | No | After relapse | CR2 | 112 | — | CR2 | 214 | Concordant |
C375 | ALL | 6 | Minor | ALL BFM 95 | 6800 | No | Frontline | CR2 | 33 | — | CR2 | 198 | Concordant |
C429 | ALL | 4 | Minor | ALL BFM 95 | 100 900 | No | After relapse | CR2 | 33 | — | CR2 | 194 | Discordant |
C438 | ALL | 10 | Minor | ALL BFM 95 | 32 000 | No | Frontline | CR2 | 15 | 46 | Exitus | — | Concordant |
C533 | ALL | 9 | Minor | ALL BFM 95 | 41 600 | No | Frontline | CR1 | 27 | 28 | Exitus | — | Concordant |
C658 | ALL | 11 | Minor | ALL IC-BFM 2002 | 40 000 | No | After relapse | CR2 | 26 | — | CR2 | 160 | Discordant |
C710 | ALL | 12 | Major | EsPhALL | 139 000 | No | Frontline | CR1 | — | — | CR1 | 153 | Concordant |
C718 | ALL | 4 | Minor | EsPhALL | 24 900 | No | Frontline | CR1 | — | — | CR1 | 152 | Concordant |
C769 | ALL | 14 | Minor | EsPhALL | 45 000 | Yes | Frontline | CR1 | 17 | 19 | Exitus | — | Concordant |
C825 | ALL | 5 | Minor | EsPhALL | 145 000 | No | Frontline | CR1 | 18 | 19 | Exitus | — | Concordant |
C861 | ALL | 17 | Major | ALL IC-BFM 2002 | 190 800 | Yes | Frontline | CR1 | — | — | CR1 | 137 | Concordant |
C1029 | ALL | 13 | Major | EsPhALL | 135 000 | No | Frontline | CR1 | — | 18 | Exitus | — | Concordant |
C1092 | ALL | 4 | Minor | EsPhALL | 184 700 | No | Frontline | CR1 | 10 | 10 | Exitus | — | Discordant |
C1277 | ALL | 3 | Minor | EsPhALL | 154 000 | No | Frontline | CR1 | — | 12 | Exitus | — | Concordant |
C1304 | ALL | 2 | Minor | COG AALL0622 | 133 630 | Yes | Frontline | CR1 | 31 | — | CR3 | 87 | Concordant |
C1382 | ALL | 5 | Minor | EsPhALL | 9500 | Yes | Frontline | No | — | 3 | Exitus | — | Discordant |
C1519 | ALL | 4 | Minor | EsPhALL | 344 000 | No | Frontline | CR2 | 34 | 42 | Exitus | — | Concordant |
C1822 | ALL | 11 | Minor | EsPhALL | 411 500 | Yes | Frontline | CR2 | 28 | — | CR2 | 45 | Concordant |
C1893 | ALL | 17 | Minor | EsPhALL | 6670 | No | Frontline | No | — | — | CR1 | 40 | Discordant |
C1964 | ALL | 14 | Minor | EsPhALL | 5900 | No | Frontline | CR1 | — | — | CR1 | 36 | NA* |
C2248 | ALL | 10 | Minor | EsPhALL | 155 200 | No | Frontline | No | — | — | CR1 | 20 | Concordant |
C2294 | ALL | 14 | Major | EsPhALL | 65 600 | Yes | Frontline | No | — | — | CR1 | 20 | Concordant |
G001 | ALL | 7 | Major | ALL BFM 2000 | 46 000 | No | No | CR1 | — | — | CR1 | 145 | Discordant |
G002 | ALL | 16 | Major | ALL BFM 2000 | 135 000 | Yes | Frontline | CR1 | 14 | 46 | Exitus | — | Discordant |
G003 | ALL | 3 | Minor | ALL BFM 2000 | 1950 | No | Frontline | CR2 | 33 | — | CR2 | 140 | Discordant |
G004 | ALL | 14 | Major | EsPhALL | 49 600 | No | Frontline | CR1 | — | — | CR1 | 98 | Discordant |
G005 | ALL | 14 | Major | EsPhALL | 167 900 | No | Frontline | CR1 | — | — | CR1 | 67 | Discordant |
G006 | ALL | 18 | Minor | EsPhALL | 760 | No | Frontline | CR2 | 84 | — | CR2 | 92 | Discordant |
C543 | CML | 12 | Major | ALL BFM 95 | 194 200 | No | Frontline | CR1 | 9 | 12 | Exitus | — | Discordant |
C1123 | CML | 6 | Major | CML PaedII-06 | 575 000 | No | Frontline | CR2 | 2 | — | CR2 | 108 | Discordant |
C1437 | CML | 14 | Major | EsPhALL | 477 000 | No | Frontline | CR1 | 11 | 13 | Exitus | — | Discordant |
A (Australian) and C (Czech) ALL patients (top 42 rows) represent unselected cohorts; G (German) ALL patients were selected based on discordance.
CNS, central nervous system; CR, complete remission; DG, diagnosis; mo, months from diagnosis; NA, not applicable (no Ig/TCR target); UPN, unique patient number; WBC, white blood cell count [×109/L].
”Discordant” based on flow cytometric MRD vs genomic BCR-ABL1 breakpoint quantification.